Update on adjuvant chemotherapy for early breast cancer
Adjuvant chemotherapy represents a significant advance in the management of early-stage breast cancer and, as such, has saved many lives. Worldwide, adjuvant chemotherapy has benefitted all groups tested, including pre- and postmenopausal women, those with node-negative and node-positive disease, an...
Saved in:
Published in | Oncology (Williston Park, N.Y.) Vol. 14; no. 9; p. 1267 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
United States
01.09.2000
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | Adjuvant chemotherapy represents a significant advance in the management of early-stage breast cancer and, as such, has saved many lives. Worldwide, adjuvant chemotherapy has benefitted all groups tested, including pre- and postmenopausal women, those with node-negative and node-positive disease, and those with estrogen-receptor (ER)-positive and ER-negative disease. However, the significant number of women who relapse despite adjuvant therapy provides the impetus to develop more efficacious regimens. Results from large randomized clinical trials, which will mature over the next few years, will clarify the potential benefits of the taxanes in the adjuvant setting, provide answers as to the efficacy of a dose-dense approach, and define a role, if any, for high-dose chemotherapy. A shift toward targeted therapies has also begun, with the incorporation of trastuzumab (Herceptin) into the adjuvant setting. Minimizing the long-term toxicity of adjuvant therapy for the large number of women who survive their disease is paramount. This article highlights the need to develop predictive factors to help tailor individual therapy. |
---|---|
AbstractList | Adjuvant chemotherapy represents a significant advance in the management of early-stage breast cancer and, as such, has saved many lives. Worldwide, adjuvant chemotherapy has benefitted all groups tested, including pre- and postmenopausal women, those with node-negative and node-positive disease, and those with estrogen-receptor (ER)-positive and ER-negative disease. However, the significant number of women who relapse despite adjuvant therapy provides the impetus to develop more efficacious regimens. Results from large randomized clinical trials, which will mature over the next few years, will clarify the potential benefits of the taxanes in the adjuvant setting, provide answers as to the efficacy of a dose-dense approach, and define a role, if any, for high-dose chemotherapy. A shift toward targeted therapies has also begun, with the incorporation of trastuzumab (Herceptin) into the adjuvant setting. Minimizing the long-term toxicity of adjuvant therapy for the large number of women who survive their disease is paramount. This article highlights the need to develop predictive factors to help tailor individual therapy. |
Author | Swain, S M McCarthy, N J |
Author_xml | – sequence: 1 givenname: N J surname: McCarthy fullname: McCarthy, N J organization: Medicine Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA – sequence: 2 givenname: S M surname: Swain fullname: Swain, S M |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/11033824$$D View this record in MEDLINE/PubMed |
BookMark | eNo1j8lqwzAUAHVIaZbmF4p-wPC0WdKxhG4Q6KU5hyfpiSTEspGdgv--hbanOQwMzJotSl9owVbgPDQevFiy9TheAGTbgrtnSyFAKSf1itnDkHAi3heO6XL7wjLxeKKun05UcZh57isnrNeZh0o4_lgskeoDu8t4HWn7xw07vDx_7t6a_cfr--5p3wwS7NTEkFP0uTVIkIMWjoLyCmLS0ViyUigTTQ4-OjTWWTJZp9Ba0IIAUGW5YY-_3eEWOkrHoZ47rPPx_0B-A4XyQ2U |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Medicine |
ExternalDocumentID | 11033824 |
Genre | Journal Article Review |
GroupedDBID | --- 04C 29N 2WC 3V. 5RE 7RV 7X7 88E 8AO 8C1 8FI 8FJ AAQQT AAWTL ABUWG ADBBV AFKRA AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS BENPR BKEYQ BMSDO BPHCQ BVXVI CCPQU CGR CUY CVF EBD EBS ECM EIF EIHBH EJD EMOBN EX3 F5P FRP FYUFA HMCUK IAO IEA IHR IHW INH INR IOF IPO ITC M1P NAPCQ NPM OK1 PQQKQ PROAC PSQYO RUL SV3 UDS UKHRP WOW |
ID | FETCH-LOGICAL-p207t-cbfdc9f65ae0fb418eb3930cd4c57e72135c5fb9c8a5787e5f4db67041e00a3f2 |
ISSN | 0890-9091 |
IngestDate | Sat Sep 28 07:36:35 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 9 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-p207t-cbfdc9f65ae0fb418eb3930cd4c57e72135c5fb9c8a5787e5f4db67041e00a3f2 |
PMID | 11033824 |
ParticipantIDs | pubmed_primary_11033824 |
PublicationCentury | 2000 |
PublicationDate | 2000-09-01 |
PublicationDateYYYYMMDD | 2000-09-01 |
PublicationDate_xml | – month: 09 year: 2000 text: 2000-09-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Oncology (Williston Park, N.Y.) |
PublicationTitleAlternate | Oncology (Williston Park) |
PublicationYear | 2000 |
References | Oncology (Huntingt) 2000 Dec;14(12):1697 |
References_xml | |
SSID | ssj0026608 |
Score | 1.6534071 |
SecondaryResourceType | review_article |
Snippet | Adjuvant chemotherapy represents a significant advance in the management of early-stage breast cancer and, as such, has saved many lives. Worldwide, adjuvant... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 1267 |
SubjectTerms | Antineoplastic Agents - therapeutic use Breast Neoplasms - drug therapy Chemotherapy, Adjuvant Clinical Trials as Topic Female Humans |
Title | Update on adjuvant chemotherapy for early breast cancer |
URI | https://www.ncbi.nlm.nih.gov/pubmed/11033824 |
Volume | 14 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ1JS8NAFMcHFxAv4r7LHLxJZJpMMp2jFKUIrYIt9FZmPQhNe4gIfnrfLElDUVEvoWRCSeeXPP7v9S0IXUtWEC2FSARjLKE0twkvKElSkMZaaJJL6bMthkV_TB8n-WQ5GtFXl1TyVn18WVfyH6pwDri6Ktk_kG2-FE7AZ-ALRyAMx18xHi-cv-7i_UK_voEmrm6AwSwWVYVUTOM7GEuXe165FC8V03GjIH0qVejCBErTx158n41nsZzN04oVDFQP7iJwGbb-UHoXoRPBS4yt1lEE0qRJNcaGk4STMDmrsYy09QTwlpnrpGGGRmuPFzO_yaAmwOkNZdE_r660ua6X1tE66zpTNXRhl-g5F4UfLdjcpGv1Gq9fcQe8LBjtop2o5_FdgLOH1ky5j7YGMWPhALHACM9LXDPCbUYYGGHPCAdGODA6ROOH-1Gvn8RhFckiJaxKlLRacVvkwhAraadrZMYzojRVOTPgZ2e5yq3kqiuckTS5pVoWjNCOIURkNj1CG-W8NCcIW2vhndGu156mRmVSZhY0BBUdTjPF01N0HH7ydBE6kkzrzTj7duUcbS-xX6BNC6-AuQQ9Vckrv9efp7kfkA |
link.rule.ids | 786 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Update+on+adjuvant+chemotherapy+for+early+breast+cancer&rft.jtitle=Oncology+%28Williston+Park%2C+N.Y.%29&rft.au=McCarthy%2C+N+J&rft.au=Swain%2C+S+M&rft.date=2000-09-01&rft.issn=0890-9091&rft.volume=14&rft.issue=9&rft.spage=1267&rft_id=info%3Apmid%2F11033824&rft_id=info%3Apmid%2F11033824&rft.externalDocID=11033824 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0890-9091&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0890-9091&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0890-9091&client=summon |